Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Study Overview
=================
Brief Summary
-----------------
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Detailed Description
-----------------
The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Official Title
-----------------
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Conditions
-----------------
Breast Cancer, Colorectal Cancer, Pancreas Cancer, Kidney Cancer, Prostate Cancer, Ovary Cancer, Head and Neck Cancer, Leukemia, Lymphoma, Lung Cancer, Melanoma, Solid Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histological and cytological confirmation of blood or solid tumor malignancies. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: existing data that satisfies the minimal requirements of a gold standard case, AND/OR previously collected and sufficient biospecimens (tumor and/or blood samples) for whole-genome and transcriptome sequencing and immunophenotype characterization, AND/OR new blood collection and/or tumor biopsy Agrees to share anonymized clinical and genomic data. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MOHCCN-O<br>Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases |  | 5 years | 
| Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions | Health technology assessment tools will be used to evaluate the real-world value of precision medicine | 5 years | 
| Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine | Health technology assessment tools will be used to evaluate the real-world value of precision medicine | 5 years |